Consumer medicine information

Konakion MM 10 mg/mL Solution for injection

Phytomenadione

BRAND INFORMATION

Brand name

Konakion MM

Active ingredient

Phytomenadione

Schedule

Unscheduled

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Konakion MM 10 mg/mL Solution for injection.

1. Why am I using KONAKION® MM?


KONAKION® MM contains the active ingredient phytomenadione. KONAKION® MM is used to treat excessive bleeding problems.
For more information, see Section 1. Why am I using KONAKION® MM? in the full CMI.

2. What should I know before I use KONAKION® MM?


Do not use if you have ever had an allergic reaction to KONAKION® MM or any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.
For more information, see Section 2. What should I know before I use KONAKION® MM? in the full CMI.

3. What if I am taking other medicines?


Some medicines may interfere with KONAKION® MM and affect how it works.
A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use KONAKION® MM?

  • KONAKION® MM is given as an injection or as a liquid for you to swallow.
  • If you receive KONAKION® MM as a liquid to swallow it will be administered with a suitable measuring device. It should be followed with a drink such as water.
  • If you receive KONAKION® MM as an injection your doctor will usually prescribe a single injection or short course of injections.
  • Your doctor will decide which is the best way for you to receive KONAKION® MM. KONAKION® MM should be used exactly as your doctor has prescribed.

More instructions can be found in Section 4. How do I use KONAKION® MM? in the full CMI.

5. What should I know while using KONAKION® MM?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using KONAKION® MM.
  • Tell your doctor if you feel the injection is not helping your condition and be sure to keep all of your appointments.
Things you should not do
  • Do not take any other medicines whether they require a prescription or not without first telling your doctor or consulting a pharmacist.
Driving or using machines
  • There is no information on use of KONAKION® MM with driving or operating machines.
Looking after your medicine
  • KONAKION® MM will be stored in the pharmacy, or at the doctors surgery.
  • Store KONAKION® MM in a cool dry place where the temperature stays below 25°C.
  • KONAKION® MM should be protected from light.

For more information, see Section 5. What should I know while using KONAKION® MM? in the full CMI.

6. Are there any side effects?


KONAKION® MM can cause serious allergic reactions.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

BRAND INFORMATION

Brand name

Konakion MM

Active ingredient

Phytomenadione

Schedule

Unscheduled

 

1 Name of Medicine

Phytomenadione (vitamin K1).

2 Qualitative and Quantitative Composition

Konakion MM contains as the active ingredient phytomenadione (vitamin K1) which is 2-methyl- 3-phytyl- 1,4-naphthaquinone. Phytomenadione is a clear, yellow, very viscous, odourless or nearly odourless oil with a molecular weight of 450.7. It is insoluble in water, soluble 1 in 70 in alcohol, more soluble in dehydrated alcohol; soluble in benzene, chloroform, ether and vegetable oils. It is stable in air but decomposes on exposure to light.
The ampoule contains the active ingredient phytomenadione 10 mg/1 mL in a mixed micelles (MM) solution (the micelles are composed of glycocholic acid and lecithin in an aqueous solution).
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Solution.

4 Clinical Particulars

4.9 Overdose

There is no known clinical syndrome attributable to hypervitaminosis of vitamin K1. Reintroduction of anticoagulation may be affected.
Treatment of suspected overdose should consist of general supportive measures.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. No data available.
Carcinogenicity. No studies on the potential carcinogenic activity of phytomenadione have been conducted.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSPHYTOM.gif CAS number. CAS-84-80-0.

7 Medicine Schedule (Poisons Standard)

Unscheduled.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/KONAKIST.gif